GlassScriptPhysician profile
Lisa Ann Bledsoe
NPI 1740267178
$10,708.86
in general payments reported to CMS, 2019-2025
47 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,147 · 2020: $1,558 · 2021: $1,088 · 2022: $2,155 · 2023: $2,353 · 2024: $987 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,761.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,335.72 | 2021-2025 | Vraylar, Qulipta, Viberzi |
| Novo Nordisk INC | $1,061.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $880.81 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $832.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Supernus Pharmaceuticals, INC. | $622.74 | 2021-2023 | Qelbree |
| Glaxosmithkline, LLC. | $616.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.34 | 2019-2025 | Jardiance |
| Allergan, INC. | $462.38 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $442.92 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $440.34 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.93 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $287.67 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.16 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $219.35 | 2019-2022 | |
| Corium, LLC | $202.75 | 2022-2023 | Azstarys |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Bledsoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.